MapLight Therapeutics Plunges 68% After Phase 2 Schizophrenia Drug Misses Primary Endpoint
Updated
Updated · CNBC · Jul 27
MapLight Therapeutics Plunges 68% After Phase 2 Schizophrenia Drug Misses Primary Endpoint
1 articles · Updated · CNBC · Jul 27
Summary
MapLight Therapeutics shares sank 68% in midday trading after its once-daily schizophrenia treatment failed to meet the primary endpoint in a Phase 2 trial.
Phase 2 results also showed mild side effects occurred more often than with placebo, adding to investor concern over the drug's risk-benefit profile.
The drop made MapLight one of the session's biggest movers, with biotech trading also shaped by deal activity such as Argenx's $2.2 billion cash acquisition of Forte Biosciences.